Can you switch between refrigerated and room temperature storage
The first biosimilar semaglutide products are not expected before the early 2030s at the earliest, and even then, biosimilar pricing typically settles at only 20-40% below the reference product due to the ongoing costs of biologic manufacturing
Novo Nordisk, the company behind both Ozempic and Wegovy, has seen its stock price skyrocket in recent years
More recently, tirzepatide, which targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, has received approval for treating type 2 diabetes and/or obesity
Holick, New England Journal of Medicine , 2007)
Bresciana-Pahor N, Forcolin M, Marzilli LG, Randaccio L, Summers MF, Toscano PJ